drugset / Trial / NCT00174252

Study Aimed At Improving Height With Genotonorm In Children Born Little And/Or Light With Growth Retardation At The Age

NCT00174252

Phase 3 Completed 57 enrolled Pfizer
Non-randomizedSingle-groupOpen-labelTreatment

Summary

To estimate the percentage of children with serum IGF-1 \> 2 standard deviation (compared to a child of the same gender and age and without growth hormone (GH) deficiency) 9 months and 12 months after initiation of GH treatment.

Timeline

Start
2005-02
Primary completion
2009-04
Completion
2009-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Somatropin Protein / enzyme biologic 0.4 mg/kg Subcutaneous